GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT02698553
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT02691325
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.
- Conditions
- Streptococcus AgalactiaeBacterial Infection Due to Streptococcus, Group B
- Interventions
- Biological: GBS Trivalent Vaccine
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT02690181
- Locations
- 🇧🇪
GSK Investigational Site, Ghent, Belgium
Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.
- Conditions
- Herpes Zoster
- Interventions
- Biological: Herpes Zoster Vaccine GSK1437173A
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8687
- Registration Number
- NCT02690207
- Locations
- 🇬🇧
GSK Investigational Site, Newtonabbey, United Kingdom
A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution
- Conditions
- Infections, Respiratory Tract
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 46
- Registration Number
- NCT02688361
- Locations
- 🇩🇪
GSK Investigational Site, Erfurt, Thueringen, Germany
A Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Healthy Adult Smokers
- Conditions
- Tobacco Use Disorder
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT02688374
- Locations
- 🇨🇳
GSK Investigational Site, Beijing, China
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 103
- Registration Number
- NCT02689206
- Locations
- 🇪🇸
GSK Investigational Site, Valladolid, Spain
A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
- Conditions
- Hypertension, Pulmonary
- Interventions
- Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 112
- Registration Number
- NCT02688387
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 308
- Registration Number
- NCT02683746
- Locations
- 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States
A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 44
- Registration Number
- NCT02683785
- Locations
- 🇬🇧
GSK Investigational Site, York, United Kingdom